Invivyd, Inc. (IVVD) Q3 2024 Earnings Call Transcript Summary
Invivyd, Inc. (IVVD) Q3 2024 Earnings Call Transcript Summary
Invivyd is focused on scaling the impact of its product PEMGARDA.The following is a summary of the Invivyd, Inc. (IVVD) Q3 2024 Earnings Call Transcript:
以下是Invivyd公司（IVVD）2024年第三季度業績會會議記錄的摘要：
Financial Performance:
財務表現:
Invivyd reported Q3 2024 revenue from its product PEMGARDA at $9.3 million.
The company noted its cash at the end of September as approximately $107 million and expects to finish the year with cash and cash equivalents of over $65 million.
Invivyd報告2024年第三季度來自其產品PEMGARDA的營業收入爲930萬美元。
公司在9月底時的現金約爲10700萬美元，預計年末將持有超過6500萬美元的現金及現金等價物。
Business Progress:
業務進展：
Invivyd is focused on scaling the impact of its product PEMGARDA.
The company reported substantial protection and reduction in risk of symptomatic COVID-19 from its CANOPY Phase 3 clinical trial.
PEMGARDA's strong efficacy data leads to continual support and development, particularly acknowledging its sustained protection, even post-dosing.
Invivyd has begun the first-in-human study for VYD2311, aiming to improve administration methods beyond intravenous to include intramuscular and subcutaneous.
Invivyd專注於擴大其產品PEMGARDA的影響力。
公司報告了其CANOPY三期臨床試驗在症狀性COVID-19方面的顯著保護效果和風險降低。
PEMGARDA強勁的療效數據促使持續的壓力位和開發，特別是承認其在給藥後仍能維持的保護效果。
Invivyd已經開始了VYD2311的首次人體研究，旨在改進給藥方法，不僅限於靜脈給藥，還包括肌肉注射和皮下給藥。
Opportunities:
機會：
Invivyd sees an opportunity to solidify its position in the market for COVID-19 treatments, especially for immunocompromised populations, through both its existing product PEMGARDA and its next-gen antibody VYD2311.
The company is expanding its reach through partnerships with community and independent infusion centers, academic centers, and a growing digital presence.
Invivyd看到有機會通過其現有產品PEMGARDA和下一代抗體VYD2311，鞏固其在COVID-19治療市場中的地位，尤其是針對免疫系統受損的人群。
該公司通過與社區和獨立輸液中心、學術中心的合作以及日益增長的數字化存在，擴展其影響力。
Risks:
風險：
Invivyd faces uncertainties with regulatory perceptions and acceptance, especially following a misinformation event pertaining to its product's efficacy, which impacted its service to the immunocompromised community.
Invivyd面臨監管認知和接受度的不確定性，尤其是在發生與其產品療效相關的信息誤導事件後，這影響了其對免疫系統受損者社區的服務。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
